Dr Fred S APPLE
Fred S. Apple, Ph.D., formerly Medical Director of Clinical Laboratories, is currently Co-Director Clinical & Forensic Toxicology Laboratory
Hennepin Healthcare/Hennepin County Medical Center
Principal InvestigatorCardiac Biomarkers Trials Laboratory (CBTL)
Hennepin Healthcare Research Institute (HHRI)
Professor, Laboratory Medicine & Pathology University of Minnesota
Co-Director Clinical & Forensic Toxicology Laboratory
Hennepin Healthcare/Hennepin County Medical Center
Forensic Toxicology Consultant to the Hennepin County Medical Examiner’s Office
Dr. Apple’s research interests have been centered in the areas of cardiac biomarkers in acute coronary syndrome and heart failure, and forensic toxicology. His CLIA-certified research laboratory is the “Cardiac Biomarkers Trials Lab” at the Hennepin Healthcare Research Institute of Hennepin County Medical Center/Hennepin Healthcare.
Dr. Apple has served as
- Associate Editor of Clinical Chemistry for the past 25 years
- Member of the ‘Universal Definition of Myocardial Infarction and Myocardial Injury’ Global Task Force
- Chair of the IFCC Committee on Clinical Application of Cardiac Biomarkers
- Member of the AACC Academy Laboratory Medicine Practice Guidelines for Myocardial Infarction and Heart Failure
- Member Steering Committee of the British Heart Foundation HighSTEACS trial
- PI of the UTROPIA and CONTRAST clinicaltrials.gov studies
- Member Institute of Medicine’s Committee on Qualification of Biomarkers as Surrogate Endpoints of Chronic Disease Risk
- Member NHLBI Working Group for Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care
- Program Co-Director of the Clinical Chemistry COMACC Fellowship at Hennepin County Medical Center.
Professor Rick BODY
Professor Rick BODY
MB ChB MRCSEd FRCEM PhD
Professor and Honorary Consultant in Emergency Medicine
University of Manchester
Division of Cardiovascular Science. Correspondence to: Emergency Department
Manchester Royal Infirmary, Manchester, UK
Rick Body is a Professor of Emergency Medicine at the University of Manchester, Professor of the Royal College of Emergency Medicine and Director of the Diagnostics and Technology Accelerator (DiTA). Professor Body has been Scientific Chair for the European Society for Emergency Medicine Annual Congress since 2014 and sits on the International Federation for Clinical Chemistry Committee for Cardiac Biomarkers. He is Deputy Editor at the Emergency Medicine Journal and Deputy National Specialty Lead for Injuries & Emergencies research with the UK National Institute for Health Research (NIHR). Professor Body’s main research interest is in the early diagnosis of acute coronary syndromes. He pioneered the use of very low troponin concentrations to ‘rule out’ acute myocardial infarction with a single blood test. He also developed the Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid, which uses machine learning to optimize early diagnosis.
Dr Robert H CHRISTENSON
Robert H Christenson, Ph.D., DABCC, FACB
Dr. Christenson is Professor of Pathology and Professor of Medical and Research Technology at the University of Maryland School of Medicine in Baltimore, Maryland. Clinically, Dr. Christenson is Medical Director of the Core Laboratories and Point of Care Testing at the University of Maryland Medical Center. He is also director of the University of Maryland’s ComACC postdoctoral training program. Academically, Dr. Christenson has published over 315 peer-reviewed papers, 6 books, 34 textbook chapters and holds 4 patents. He has an active research program in the area of biomarkers of heart disease, renal disease and stroke. Dr. Christenson has a long standing interest in Evidence-Based Laboratory Medicine and has chaired both AACC and International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) committees on this topic. He also serves as chair of the IFCC’s task force for Standardization of Cardiac Troponin I and is currently a member of the IFCC and AACC nominating committees. Dr. Christenson has served as chair of the Cardiac Biomarkers of Myocardial Injury Guidelines, and he is currently Co-chair of the AACC Academy’s update for Guidelines of Cardiovascular disease, which includes the biomarkers for Acute Coronary Syndrome and Heart Failure. Dr. Christenson also co-chaired the NACB’s Laboratory Medicine Practice Guidelines on use of lipids for cardiovascular disease. Dr. Christenson has held a number of leadership positions with professional organizations including on the Board of Directors of Professional Societies including two terms with the American College of Cardiology – Accreditation Management Board. Dr. Christenson has been particularly active in his ‘home’ professional association-The American Association for Clinical Chemistry (AACC). He has served on AACC’s the Board of Directors and as Secretary of the association. In 2013 he served as AACC’s President. Dr. Christenson has also been engaged with peer-reviewed journals including on the Board of Editors for Clinical Chemistry, and was an Associate Editor of Clinical Biochemistry for over 25 years. Dr. Christenson is currently the Editor-in-Chief of the AACC publication, the Journal of Applied Laboratory Medicine. Dr. Christenson has presented at AACC, ACC, AHA, ESC, CAP, ASCP and many other professional meetings on the clinical measurement, interpretation and utilization of cardiac troponin, N-terminal pro B-type Natriuretic Peptide and other biomarkers. Dr. Christenson has also presented information on clinical use of cardiac biomarkers for many educational audioconferences, Public Television Series and Medscape.
Professor P O COLLINSON
Professor P O Collinson MA MB BChir FRCPath MD FACB FRCP edin.EurClinChem FESC is Consultant Chemical Pathologist at St George’s Hospital and Professor of Cardiovascular Biomarkers at St George’s Medical School. He is responsible for the Clinical services of the Blood Sciences laboratory and provides the Vascular Risk management service for the Cardiac Department.
He has published over 200 papers and review articles, over 220 abstracts and 15 book chapters. Likes SCUBA diving and photographing sharks. Especially the ones with big teeth.
Dr Allan S JAFFE
Allan S. Jaffe, M.D., is a Consultant and Professor of Medicine in the Department of Cardiovascular Diseases at the Mayo Clinic in Rochester, Minnesota. He has a joint appointment and is a Professor of Laboratory Medicine and Pathology and Chair of the Division of Clinical Core Laboratory Services
Dr Jaffe’s research interests include a long academic career investigating the use of biomarkers to characterize the pathobiology of acute cardiovascular disease. With investigators at Washington University in St. Louis, he helped develop and was responsible for the validation studies of the first cardiac troponin I assay. His cutting-edge research explores questions surrounding many commonly used cardiac biomarkers.
Dr Jaffe is an esteemed national and international presenter who has co-authored five books and written more than 500 peer-reviewed articles, book chapters, and abstracts. His writings particularly focus on the use of both cardiac troponin and natriuretic peptides to characterize patients with both acute and chronic heart failure. Dr Jaffe has received many awards and honors throughout his career including the Gifted Teacher award in 2018 from the American College of Cardiology and the Career Achievement Award in a Defined Area of Research from the American Association of Clinical Chemistry. He is simply the ultimate authority on the use of many of these markers in the clinical arena and for that reason serves on many of the national and international groups who make guidelines in this area.
Dr Jaffe completed his undergraduate studies at University of Maryland where he also earned his medical degree. He trained at Washington University School of Medicine in St. Louis, Missouri for house staff, Chief Residency and fellowship training and was on the faculty there for 22 years, rising to the rank of Professor of Medicine. He left in 1995 to become Chief to Cardiology and Associate Chair of Medicine for Academic Affairs at the State University of New York at Syracuse in 1995. In 1999, he was recruited to the Mayo Clinic in Cardiology and Laboratory Medicine.
Professor Michael MARBER
Professor of Cardiology, Honorary Consultant Cardiologist
Professor Mike Marber, BSc MBBS PhD FRCP, is a physician scientist with basic research interests in the processes causing heart cell death and clinical interests in patient care during and after acute myocardial infarction.
Mike Marber graduated from the Middlesex Hospital Medical School, London in 1984 having intercalated a BSc in Biophysics. After clinical training at the Brompton, St Peter’s and St George’s Hospitals he completed a PhD in physiology at University College London and postdoctoral training at University of California, San Diego. In 1996 he was appointed as a Senior Lecturer at King’s College London & Consultant Cardiologist as Guy’s and St Thomas’ NHS Trust he was subsequently promoted to Professor of Cardiology in 1999.
Mike Marber leads an interdisciplinary research group with interests in biomarkers of myocardial injury and drug discovery focusing on myocardial infarction and heart failure. Translational efforts focus are on using cardiac myosin-binding protein C (cMyC) to triage patients with chest pain and finding small molecules to disrupt the interaction between p38α mitogen-activated protein kinase (p38α) and TGF-beta activated kinase 1 binding protein 1 (TAB1).
Professor Nicholas L MILLS
Professor Nicholas L MILLS, Edinburgh, UK
Usher Institute of Population Health Sciences and Informatics
& BHF Centre for Cardiovascular Science
Professor Mills is a Professor of Cardiology at the University of Edinburgh, a British Heart Foundation Senior Clinical Research Fellow, and a Consultant Interventional Cardiologist at the Royal Infirmary of Edinburgh. He is also Academic Lead and Senior Responsible Officer for the University of Edinburgh’s Health and Social Care Data Driven Innovation Hub at the Usher Institute.
His research aims to use linked regional and national healthcare data in Scotland to develop novel tools for diagnosis and risk stratification for cardiovascular disease, and to evaluate their impact on clinical outcomes in practice. He is the chief investigator of a series of multi-centred cluster randomised trials that use routine electronic health record data to evaluate the impact of high-sensitivity cardiac troponin testing on outcomes in patients with suspected acute coronary syndrome. His research is supported by project grants and research fellowships from the British Heart Foundation. Further information is available at www.highsteacs.com or through our Twitter feed @highSTEACS or @troponinpapers
Mr Alan REID
Mr Alan REID Scheme Organiser UK NEQAS Cardiac Marker Service
Alan Reid is a Clinical Scientist within the Biochemistry Department, Queen Elizabeth University Hospital , NHS Greater Glasgow & Clyde. Research interests in the use of cardiac biomarkers in acute coronary syndrome and heart failure. From 1997 developed an interest in the development of cardiac marker EQA. I am member of European Metrology Programme for Innovation and Research (EMPIR) project: Providing the measurement infrastructure to allow quantitative diagnostic methods for biomarkers of coronary heart diseases. This EMPIR initiative is co-funded by the European Union’s Horizon 2020 research and innovation programme. As Scheme Organiser of UK NEQAS Cardiac Marker Service continue to develop EQA schemes for both laboratory and point of care systems with current and future cardiac biomarkers. Develop current interpretative exercises to assist in clinical interpretation of cardiac biomarker testing.